These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
496 related articles for article (PubMed ID: 30827888)
1. Hacking the Cancer Genome: Profiling Therapeutically Actionable Long Non-coding RNAs Using CRISPR-Cas9 Screening. Esposito R; Bosch N; Lanzós A; Polidori T; Pulido-Quetglas C; Johnson R Cancer Cell; 2019 Apr; 35(4):545-557. PubMed ID: 30827888 [TBL] [Abstract][Full Text] [Related]
2. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Zhu S; Li W; Liu J; Chen CH; Liao Q; Xu P; Xu H; Xiao T; Cao Z; Peng J; Yuan P; Brown M; Liu XS; Wei W Nat Biotechnol; 2016 Dec; 34(12):1279-1286. PubMed ID: 27798563 [TBL] [Abstract][Full Text] [Related]
3. State of the art technologies to explore long non-coding RNAs in cancer. Salehi S; Taheri MN; Azarpira N; Zare A; Behzad-Behbahani A J Cell Mol Med; 2017 Dec; 21(12):3120-3140. PubMed ID: 28631377 [TBL] [Abstract][Full Text] [Related]
4. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research. Zhen S; Li X Hum Gene Ther; 2019 Jan; 30(1):3-9. PubMed ID: 30045635 [TBL] [Abstract][Full Text] [Related]
5. CRISPR links to long noncoding RNA function in mice: A practical approach. Miano JM; Long X; Lyu Q Vascul Pharmacol; 2019 Mar; 114():1-12. PubMed ID: 30822570 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer. Zhen S; Hua L; Liu YH; Sun XM; Jiang MM; Chen W; Zhao L; Li X Oncotarget; 2017 Feb; 8(6):9634-9646. PubMed ID: 28038452 [TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNAs as novel therapeutic targets in cancer. Lavorgna G; Vago R; Sarmini M; Montorsi F; Salonia A; Bellone M Pharmacol Res; 2016 Aug; 110():131-138. PubMed ID: 27210721 [TBL] [Abstract][Full Text] [Related]
8. Induced mutation and epigenetics modification in plants for crop improvement by targeting CRISPR/Cas9 technology. Khan MHU; Khan SU; Muhammad A; Hu L; Yang Y; Fan C J Cell Physiol; 2018 Jun; 233(6):4578-4594. PubMed ID: 29194606 [TBL] [Abstract][Full Text] [Related]
9. Tuning the Expression of Long Noncoding RNA Loci with CRISPR Interference. Stojic L Methods Mol Biol; 2020; 2161():1-16. PubMed ID: 32681501 [TBL] [Abstract][Full Text] [Related]
10. In Vivo Genome-Wide CRISPR Activation Screening Identifies Functionally Important Long Noncoding RNAs in Hepatocellular Carcinoma. Wong LS; Wei L; Wang G; Law CT; Tsang FH; Chin WC; Ng IO; Wong CM Cell Mol Gastroenterol Hepatol; 2022; 14(5):1053-1076. PubMed ID: 35944892 [TBL] [Abstract][Full Text] [Related]
11. A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way? Taylor J; Woodcock S J Biomol Screen; 2015 Sep; 20(8):1040-51. PubMed ID: 26048892 [TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNAs: A view to kill ovarian cancer. Zamaraev AV; Volik PI; Sukhikh GT; Kopeina GS; Zhivotovsky B Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188584. PubMed ID: 34157315 [TBL] [Abstract][Full Text] [Related]
13. CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology. Hashemi A Curr Gene Ther; 2018; 18(2):115-124. PubMed ID: 29473500 [TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9 to Silence Long Non-Coding RNAs. Rosenlund IA; Calin GA; Dragomir MP; Knutsen E Methods Mol Biol; 2021; 2348():175-187. PubMed ID: 34160807 [TBL] [Abstract][Full Text] [Related]
15. Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer. Worku T; Bhattarai D; Ayers D; Wang K; Wang C; Rehman ZU; Talpur HS; Yang L Cell Physiol Biochem; 2017; 44(3):948-966. PubMed ID: 29179183 [TBL] [Abstract][Full Text] [Related]
16. Long Noncoding RNA GMAN, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding GMAN-AS. Zhuo W; Liu Y; Li S; Guo D; Sun Q; Jin J; Rao X; Li M; Sun M; Jiang M; Xu Y; Teng L; Jin Y; Si J; Liu W; Kang Y; Zhou T Gastroenterology; 2019 Feb; 156(3):676-691.e11. PubMed ID: 30445010 [TBL] [Abstract][Full Text] [Related]
17. Targeting long non-coding RNAs in cancer therapy using CRISPR-Cas9 technology: A novel paradigm for precision oncology. Mahato RK; Bhattacharya S; Khullar N; Sidhu IS; Reddy PH; Bhatti GK; Bhatti JS J Biotechnol; 2024 Jan; 379():98-119. PubMed ID: 38065367 [TBL] [Abstract][Full Text] [Related]
18. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment. Xing H; Meng LH Acta Pharmacol Sin; 2020 May; 41(5):583-587. PubMed ID: 31792341 [TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 for overcoming drug resistance in solid tumors. Saber A; Liu B; Ebrahimi P; Haisma HJ Daru; 2020 Jun; 28(1):295-304. PubMed ID: 30666557 [TBL] [Abstract][Full Text] [Related]
20. [The application of CRISPR/Cas9 genome editing technology in cancer research]. Wang DY; Ma N; Hui Y; Gao X Yi Chuan; 2016 Jan; 38(1):1-8. PubMed ID: 26787518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]